Marianne Frydenlund

During her career, Marianne has gained a unique in-house perspective on IP-related business practices within the wireless ecosystem. At Avanci, she is developing and leading new licensing programs for the Internet of Things (IoT) beyond the automotive industry. Marianne joined Avanci from Nordic Semiconductor, where she was most recently Senior Vice President, Legal & Compliance, with responsibilities including patent licensing activities, concluding several ground-breaking agreements. Earlier in her career, Marianne worked for Huawei Technologies, Nexans Norway AS, Equinor and Aker Solutions where she focused on legal issues associated with technology-related commercial transactions. Marianne graduated from the University of Oslo School of Law. She chairs the Board of the Norwegian Company Lawyers Association (NCLA) where she has been involved in their mentoring programs aimed at helping women advance in business and technology-related careers.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More